These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 15034931

  • 21. Effects of vascular endothelial growth factor-C and -D on osteoclast differentiation and function in human peripheral blood mononuclear cells.
    Motokawa M, Tsuka N, Kaku M, Kawata T, Fujita T, Ohtani J, Matsuda Y, Terao A, Tanne K.
    Arch Oral Biol; 2013 Jan; 58(1):35-41. PubMed ID: 22771550
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.
    Quinn JM, Elliott J, Gillespie MT, Martin TJ.
    Endocrinology; 1998 Oct; 139(10):4424-7. PubMed ID: 9751528
    [Abstract] [Full Text] [Related]

  • 24. Synovial fluid macrophages are capable of osteoclast formation and resorption.
    Adamopoulos IE, Sabokbar A, Wordsworth BP, Carr A, Ferguson DJ, Athanasou NA.
    J Pathol; 2006 Jan; 208(1):35-43. PubMed ID: 16278818
    [Abstract] [Full Text] [Related]

  • 25. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo.
    Henriksen K, Gram J, Høegh-Andersen P, Jemtland R, Ueland T, Dziegiel MH, Schaller S, Bollerslev J, Karsdal MA.
    Am J Pathol; 2005 Nov; 167(5):1341-8. PubMed ID: 16251418
    [Abstract] [Full Text] [Related]

  • 26. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
    Adamopoulos IE, Wordsworth PB, Edwards JR, Ferguson DJ, Athanasou NA.
    Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
    [Abstract] [Full Text] [Related]

  • 27. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin.
    Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M.
    J Biol Chem; 2001 Apr 20; 276(16):13065-71. PubMed ID: 11278791
    [Abstract] [Full Text] [Related]

  • 28. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, Higashio K, Quinn JM, Gillespie MT, Martin TJ, Suda T, Takahashi N.
    Endocrinology; 2001 Aug 20; 142(8):3656-62. PubMed ID: 11459815
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH, Zhou HD, Yuan LQ, Xie H, Liao EY.
    Zhonghua Yi Xue Za Zhi; 2004 Dec 17; 84(24):2102-6. PubMed ID: 15730627
    [Abstract] [Full Text] [Related]

  • 31. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
    Lee SK, Kalinowski JF, Jastrzebski SL, Puddington L, Lorenzo JA.
    Endocrinology; 2003 Aug 17; 144(8):3524-31. PubMed ID: 12865334
    [Abstract] [Full Text] [Related]

  • 32. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
    Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG.
    J Cell Sci; 2006 Apr 01; 119(Pt 7):1283-96. PubMed ID: 16522681
    [Abstract] [Full Text] [Related]

  • 33. Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells.
    Alnaeeli M, Penninger JM, Teng YT.
    J Immunol; 2006 Sep 01; 177(5):3314-26. PubMed ID: 16920972
    [Abstract] [Full Text] [Related]

  • 34. Autocrine regulation of osteoclast formation and bone resorption by IL-1 alpha and TNF alpha.
    Tani-Ishii N, Tsunoda A, Teranaka T, Umemoto T.
    J Dent Res; 1999 Oct 01; 78(10):1617-23. PubMed ID: 10520966
    [Abstract] [Full Text] [Related]

  • 35. Beta-cryptoxanthin stimulates apoptotic cell death and suppresses cell function in osteoclastic cells: change in their related gene expression.
    Uchiyama S, Yamaguchi M.
    J Cell Biochem; 2006 Aug 01; 98(5):1185-95. PubMed ID: 16514646
    [Abstract] [Full Text] [Related]

  • 36. Nitric oxide: a cytokine-induced regulator of bone resorption.
    Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N.
    J Bone Miner Res; 1995 Jul 01; 10(7):1040-9. PubMed ID: 7484279
    [Abstract] [Full Text] [Related]

  • 37. Nitric oxide enhances osteoclastogenesis possibly by mediating cell fusion.
    Nilforoushan D, Gramoun A, Glogauer M, Manolson MF.
    Nitric Oxide; 2009 Aug 01; 21(1):27-36. PubMed ID: 19389479
    [Abstract] [Full Text] [Related]

  • 38. Cloning and characterization of osteoclast precursors from the RAW264.7 cell line.
    Cuetara BL, Crotti TN, O'Donoghue AJ, McHugh KP.
    In Vitro Cell Dev Biol Anim; 2006 Aug 01; 42(7):182-8. PubMed ID: 16948499
    [Abstract] [Full Text] [Related]

  • 39. 8-Nitro-cGMP is a promoter of osteoclast differentiation induced by RANKL.
    Kaneko K, Miyamoto Y, Tsukuura R, Sasa K, Akaike T, Fujii S, Yoshimura K, Nagayama K, Hoshino M, Inoue S, Maki K, Baba K, Chikazu D, Kamijo R.
    Nitric Oxide; 2018 Jan 30; 72():46-51. PubMed ID: 29183803
    [Abstract] [Full Text] [Related]

  • 40. NO-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and VASP.
    Yaroslavskiy BB, Zhang Y, Kalla SE, García Palacios V, Sharrow AC, Li Y, Zaidi M, Wu C, Blair HC.
    J Cell Sci; 2005 Dec 01; 118(Pt 23):5479-87. PubMed ID: 16291726
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.